ASH 2023 | The BPDCN multi-center collaboration and global registry program

Nerses Ghahramanyan, MD, Yeolyan Hematology and Oncology Center, Yerevan, Armenia, introduces the blastic plasmacytoid dendritic cell neoplasm (BPDCN) International Registry, a global initiative that aims to foster multicenter collaboration to create a comprehensive database of patients with this rare disease in order to develop data-driven recommendations for clinicians. An analysis of data from the registry elucidated the types of treatments used in BPDCN patients, and although acute lymphoblastic leukemia (ALL)-based treatment resulted in superior outcomes as compared to acute myeloid leukemia (AML)-based treatment, the relapse rate remained high. The novel agent tagraxofusp was administered in only a small percentage of patients, indicating that barriers to access should be addressed. Dr Ghahramanyan hopes that this registry will improve outcomes for patients by providing a greater understanding of the current treatment patterns and challenges in this disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.